



CONTENTS

LIST OF ABBREVIATION

INTRODUCTION

FOREWORD

CHAPTER 1

Registry fundamentals

- I-2 Introduction
- I-2 General registration procedures
- I-3 Population-based registries and special registries
- I-3 Formalization
- I-3 Founding
- I-3 Relations with AIRTUM
- I-4 Relations with IARC
- I-4 Relations with ENCR and IACR
- I-4 Organization
- I-4 Group structure
- I-4 Training
- I-4 Defining projects and methods
- I-5 Registries and mortality data
- I-5 Accreditation
- I-5 Rules
- I-6 Accreditation procedures and methods
- I-6 Periodic audits of accredited registries
- I-7 References

CHAPTER 2

Registration

- II-2 Reportable cases
- II-2 Incident cases
- II-3 Residence
- II-3 Laterality and paired organs
- II-3 Premalignant lesions
- II-4 Lesions of uncertain behavior
- II-4 Data sources
- II-4 Public register sources
- II-6 Mandatory sources of information
- II-6 Additional sources of information
- II-6 Critical aspects of current sources of information
- II-8 Record linkage systems
- II-8 Data collection
- II-8 Standard layout
- II-8 Incidence
- II-9 Mortality
- II-9 Populations
- II-9 A closer look at certain essential variables
- II-10 Extension and staging
- II-11 The TNM classification
- II-11 "Condensed" TNM
- II-12 Further information on extension and staging

- II-12 Treatment
- II-13 Interaction with special registries
- II-13 Screening programs
- II-15 References
- II-16 Tables

CHAPTER 3

Classification

- III-2 Introduction
- III-2 ICD-O rules
- III-3 IARC/IACR and ENCR rules
- III-3 Multiple primaries
- III-4 Evaluation for incidence
- III-5 Evaluation for registration
- III-5 Management of relapses
- III-5 Multiple primaries and survival
- III-6 Tumors with no microscopic confirmation
- III-6 Cases of uncertain interpretation
- III-6 Assignment of topography in neo-organs
- III-6 Assignment of a specific morphology in the absence of microscopic confirmation
- III-6 Markers
- III-7 Diagnostic imaging
- III-7 Endoscopic diagnostics
- III-7 Exploratory surgery/autopsy
- III-7 Clinical diagnostics and treatment
- III-7 Post-mortem diagnoses
- III-8 Cytogenetic and molecular diagnosis
- III-8 Refutable or ineffective diagnoses
- III-8 Managing special cases
- III-8 Not sure eligibility (NSE) cases
- III-9 DCI and DCO cases
- III-11 Correct coding in a few specific instances
- III-12 Special cases
- III-13 Prevalent cases
- III-13 Non resident cases at diagnosis
- III-13 Cases identified after incidence has been "closed"
- III-14 Autopsy in cancer carriers
- III-14 References
- III-15 Tables and figures

CHAPTER 4

Specific tumor sites (part 1)

- IV(1)-2 Lip cancer
- IV(1)-2 Tumors of the upper aerodigestive tract
- IV(1)-3 Salivary gland neoplasms
- IV(1)-3 Gastrointestinal cancer
- IV(1)-3 Esophagus
- IV(1)-3 Stomach
- IV(1)-4 Small intestine
- IV(1)-4 Bowel

IV(1)-7 Liver, bile ducts, and pancreas
IV(1)-7 Lung cancer
IV(1)-7 Mesothelioma
IV(1)-8 Sarcomas
IV(1)-8 Skin cancer
IV(1)-8 Melanoma
IV(1)-9 Other malignant skin tumors
IV(1)-9 Kaposi's sarcoma
IV(1)-9 Breast cancer
IV(1)-9 Registration techniques
IV(1)-10 References
IV(1)-11 Tables

CHAPTER 4

Specific tumor sites (part 2)

IV(2)-2 Cancer of the female genital organs
IV(2)-2 Cervix
IV(2)-3 Uterus
IV(2)-3 Ovary and Fallopian tube
IV(2)-3 Female genital organs, other sites
IV(2)-3 Cancer of the male genital organs
IV(2)-3 Prostate
IV(2)-4 Penis, scrotum, testicle
IV(2)-4 Urinary tract cancer
IV(2)-4 Bladder and urinary tract
IV(2)-6 Kidney
IV(2)-7 Central nervous system (CNS), peripheral nervous system, and intracranial-intraspinal neoplasms
IV(2)-7 Reportable cases
IV(2)-8 WHO histological grade
IV(2)-8 Endocrine gland neoplasms
IV(2)-8 Pituitary gland
IV(2)-8 Thyroid, parathyroid glands
IV(2)-8 Endocrine pancreas
IV(2)-8 Adrenal gland
IV(2)-8 Carcinoid tumors
IV(2)-9 References
IV(2)-10 Tables

CHAPTER 4

Specific tumor sites (part 3)

IV(3)-2 Lymphohematopoietic cancer
IV(3)-2 Lymphomas
IV(3)-10 Plasma cell, mast cell, and histiocytic neoplasms and immunoproliferative disorders
IV(3)-12 Leukemia
IV(3)-15 Chronic myeloproliferative and myelodysplastic disorders
IV(3)-18 Multiple hematological neoplasms
IV(3)-19 Outpatient incidence date
IV(3)-19 References
IV(3)-21 Tables

CHAPTER 4

Specific tumor sites (part 4)

IV-2 Rare tumors

IV-2 Childhood cancer

IV-3 Piedmont childhood cancer registry

IV-5 References

IV-6 Table

CHAPTER 5

Managing and controlling the database

V-2 Population base

V-2 Data sources and resident population present

V-2 Indicators

V-2 Number of cases

V-3 Proportional distribution

V-3 Crude rate

V-3 Standardized rate

V-3 Cumulative risk

V-3 Mortality/incidence ratio

V-3 Years of life lost/gained

V-3 Survival

V-3 Prevalence

V-3 Time trends

V-4 Standard errors and confidence intervals for the indicators

V-4 Index calculation programs

V-4 CanReg

V-4 SEERStat

V-5 Error control

V-5 Data entry procedures

V-5 Programs for controlling the precision of data

V-7 Checking the completeness of records

V-10 Revisions and updates

V-10 Follow-up

V-10 References

APPENDIX 1

APP.1-2 User's Guide to CheckRT: Software for Quality Control

APP.1-2 Importing the case file

APP.1-3 Importing mortality data

APP.1-4 Importing the population

APP.1-5 Other import features and advanced settings

APP.1-6 Analyzing the data

APP.1-8 Restrictions and system requirements

APPENDIX 2

APP.2-2 User's Guide to SALI : Software for Record Linkage

APP.2-2 Instructions for linkage using SALI

APP.2-4 Other features of the software

APP.2-5 References

APPENDIX 3

APP.3-2 User's Guide to INCAS-AIRTUM: Software for Selection of HDD and Mortality Listings

APP.3-2 Operation

APP.3-2 Note